ClariVest Asset Management LLC increased its stake in Harvard Bioscience Inc. (NASDAQ:HBIO) by 3.9% during the second quarter, Holdings Channel reports. The institutional investor owned 199,831 shares of the company’s stock after buying an additional 7,500 shares during the period. ClariVest Asset Management LLC’s holdings in Harvard Bioscience were worth $571,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently modified their holdings of the company. First Manhattan Co. bought a new position in shares of Harvard Bioscience during the second quarter valued at approximately $125,000. Geode Capital Management LLC increased its position in shares of Harvard Bioscience by 1.4% in the first quarter. Geode Capital Management LLC now owns 168,634 shares of the company’s stock valued at $509,000 after buying an additional 2,254 shares in the last quarter. State Street Corp increased its position in shares of Harvard Bioscience by 5.7% in the first quarter. State Street Corp now owns 316,644 shares of the company’s stock valued at $955,000 after buying an additional 17,018 shares in the last quarter. Foundry Partners LLC increased its position in shares of Harvard Bioscience by 0.3% in the second quarter. Foundry Partners LLC now owns 505,925 shares of the company’s stock valued at $1,447,000 after buying an additional 1,475 shares in the last quarter. Finally, Acadian Asset Management LLC increased its position in shares of Harvard Bioscience by 3.1% in the second quarter. Acadian Asset Management LLC now owns 729,779 shares of the company’s stock valued at $2,088,000 after buying an additional 21,961 shares in the last quarter. Institutional investors and hedge funds own 66.31% of the company’s stock.
Shares of Harvard Bioscience Inc. (NASDAQ:HBIO) traded up 4.25% during mid-day trading on Friday, hitting $2.70. The stock had a trading volume of 24,119 shares. The company’s market cap is $92.65 million. The stock’s 50-day moving average is $2.68 and its 200 day moving average is $2.95. Harvard Bioscience Inc. has a 12 month low of $2.41 and a 12 month high of $3.97.
Harvard Bioscience (NASDAQ:HBIO) last announced its quarterly earnings results on Thursday, July 28th. The company reported $0.03 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.03. The firm had revenue of $26.10 million for the quarter, compared to the consensus estimate of $26.60 million. Harvard Bioscience had a positive return on equity of 3.40% and a negative net margin of 18.04%. On average, equities research analysts forecast that Harvard Bioscience Inc. will post $0.16 earnings per share for the current fiscal year.
Separately, Zacks Investment Research upgraded Harvard Bioscience from a “sell” rating to a “hold” rating in a research note on Friday, September 23rd.
Harvard Bioscience Company Profile
Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of specialized products, apparatus and scientific instruments. The Company’s products are used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories across the world.